Loading
A phase 2 trial of Linperlisib in Leukaemia, run by Institute of Hematology & Blood Diseases Hospital, China, now recruiting.
Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia is a phase 2 interventional study registered as NCT06224257 by Institute of Hematology & Blood Diseases Hospital, China, with 41 participants planned, started 2023-12-03 and due to reach its primary completion in 2025-10-31. Interventions recorded: Linperlisib. Conditions recorded: Relapsed/Refractory Large Granular T Lymphocytic Leukemia.
Linked to the drug Linperlisib because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.
Shares Linperlisib and the tag pipeline.
Shares T-cell large granular lymphocytic leukaemia and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.